Powering the Immune System to Transform Lives
Selected publications
Science in the Spotlight
A Phase 2 Trial of Tobevibart Plus Elebsiran in Hepatitis Delta
This New England Journal of Medicine manuscript describes the efficacy and safety results of Vir Biotechnology’s SOLSTICE Phase 2 clinical trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta.
The data show that the majority of participants (66%; 21/32) receiving a monthly dose of the combination achieved undetectable levels of hepatitis delta virus after 48 weeks of treatment (measured as hepatitis delta virus RNA target not detected). Additionally, approximately 90% of participants achieved reductions in hepatitis B surface antigen (HBsAg), which suggests that the fundamental mechanism that the hepatitis delta virus needs to replicate may be inhibited. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations.
The combination of tobevibart and elebsiran was selected for continued development based on its overall efficacy and safety profile. It is currently being evaluated in Vir Biotechnology’s ECLIPSE registrational program for chronic hepatitis delta.
Literature Archive
HIV: human immunodeficiency virus
Vir Biotechnology has exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.